|
Omapatrilat
drug data and news
Omapatrilat drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Omapatrilat
|
| Brand Names/Synonyms |
Omapatrilat; Omapatrilat [Usan]; Vanlev |
| Indication |
For the treatment of hypertension |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Omapatrilat is used to treat hypertension. Vasopeptidase inhibitor that simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Omapatrilat lowers blood pressure by inhibiting the action of the angiotensin converting enzyme (ACE), which causes blood vessels to constrict. But unlike other drugs, omapatrilat also inhibits another enzyme known as neutral endopeptidase (NEP), which helps blood vessels relax. Omapatrilat demonstrated greater reduction in blood pressure than the ACE inhibitor lisinopril in individuals with salt-sensitive hypertension who typically do not respond well to ACE inhibitors. |
| Mechanism Of Action |
Omapatrilat binds to both angiotensin converting enzyme and neutral endopeptidase. This results in a decrease renin-angiotensin-aldosterone production and increase natriuretic peptidase circulation. |
Omapatrilat News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Not Available |
| Drug_Category |
Cardiovascular Agents; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Vasopeptidase inhibitor; Protease Inhibitors |
| Absorption |
The absolute oral bioavailability of omapatrilat is 20% to 30% and the absorption is not affected by food intake. |
| Interactions |
Drug Interactions for Omapatrilat
Drug and food interactions have not been observed with Omapatrilat drug. It is assumed that omapatrilat would have some of the same drug interactions as ACE inhibitors. Some common drug interaction for ACE inhibitors are: Allopurinol,
Aspirin,
Azathioprine,
Lithium,
Potassium supplements,
Potassium sparing diuretics,
and Trimethoprim.
No drug interaction were found when Warfarin was co-administered with omapatrilat.
|
| Toxicity |
Side effects include hyperkalemia, cough, hypotension, increased SrCr, and dizziness. Dizziness, diarrhea, vision disturbance, hypotension and angioedema |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
6-oxo-5-(3-phenyl-2-sulfanyl-propanoyl)amino-2-thia-7-azabicyclo[5.4.0]undecane-8-carboxylicacid |
| Chemical Formula |
C19H24N2O4S2 |
| Molecular Weight |
408.537 g/mol |
| Smiles String |
C1CC(N2C(C1)SCCC(C2=O)NC(=O)C(CC3=CC=CC=C3)S)C(=O)O |
| Melting Point |
Not Available |
| Water Solubility |
Not Available |
| State |
Solid |
| LogP/Hphobicity |
2.541 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Hepatic |
| Half Life |
Not Available |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00443 |
| CAS Registry Number |
167305-00-2 |
| KEGG Compound ID |
C13468 |
| PubChem ID |
SID:702772 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
